Drug-Device Combination Products in Canada: How Health Canada's Classification Framework Actually Works

A manufacturer contacts us with what sounds like a simple question: does their antibiotic-coated orthopaedic implant need a Drug Identification Number or a Medical Device Licence? Four regulatory consultations and six weeks later, they have an answer — and it’s not a clean one.

That scenario plays out more often than anyone in the industry would like to admit. Canada’s regulatory framework was built around a clean separation between drugs and medical devices, and combination products — those that integrate both — don’t fit neatly on either side. The classification decision isn’t just administrative. It determines your development timeline, your GMP obligations, your submission format, and which directorate inside Health Canada reviews your file.

What Health Canada Actually Counts as a Combination Product

Health Canada doesn’t define “combination product” in a single statute the way the US FDA does under 21 CFR Part 3. Instead, the term is used operationally across guidance documents, with the underlying principle drawn from the Food and Drugs Act (R.S.C., 1985, c. F-27) and the Medical Devices Regulations (SOR/98-282).

Broadly, a combination product in Health Canada’s framework is any product that joins a drug (or biologic) with a medical device in one of three configurations:

1. Integral combination products — the drug and device components are physically or chemically joined and intended for single use together (e.g., a drug-eluting coronary stent, a prefilled auto-injector, or a transdermal patch).
2. Co-packaged products — a device and a drug are packaged together but function independently and are separately labelled (e.g., a lidocaine vial co-packaged with an injection kit).
3. Cross-labelled products — two separately sold products where the labelling of one refers to the other as necessary for proper use (e.g., a specific drug approved for use exclusively with a named nebulizer).

These 3 configurations aren’t just definitional categories — they lead to meaningfully different regulatory outcomes and timelines. A co-packaged product with two separately approvable components is far simpler to manage than an integral combination where the mode of action is under genuine dispute. Knowing which type you have before you engage with Health Canada saves months of back-and-forth.

The Primary Mode of Action Test — Where the Hard Decisions Actually Happen

When a product is integral, Health Canada applies a primary mode of action (PMOA) analysis. The central question: does the product achieve its principal intended purpose through pharmacological, chemical, immunological, or metabolic means — or through physical, mechanical, or structural means?

If the answer is the former, the product is regulated as a drug under the Food and Drug Regulations (C.R.C., c. 870), with the device component reviewed as part of that submission. If the answer is the latter, it falls under the Medical Devices Regulations, and the drug component must still meet relevant safety and biocompatibility standards but doesn’t follow a standard New Drug Submission pathway.

A few illustrative cases worth walking through:

Drug-eluting coronary stents: The stent provides structural support to the artery wall. The drug coating — typically sirolimus or paclitaxel — reduces in-stent restenosis. Health Canada has generally classified these as Class IV medical devices, since the mechanical function is primary. But the manufacturer still needs to address the pharmacological action of the drug component, often through a parallel abbreviated drug review coordinated between the Therapeutic Products Directorate (TPD) and the Medical Devices Bureau (MDB).

Prefilled auto-injectors: Here, the drug is unambiguously the primary purpose — the syringe mechanism is a delivery system. These are regulated under the drug framework. The injector must meet device safety requirements (biocompatibility under ISO 10993 is typically referenced), but the regulatory lead is the TPD. MDB plays a supporting role at most.

Transdermal drug delivery patches: Classified as drugs. The adhesive matrix and membrane system are incidental to the pharmacological function of the active ingredient crossing the dermal barrier.

Antibiotic-loaded bone cement: This is genuinely contested territory. The mechanical bonding function of the cement may or may not outweigh the antibacterial intent depending on the clinical claim, and Health Canada has handled analogous cases on a file-by-file basis. If you’re developing one, do not assume that a European MDR or FDA 510(k) classification decision transfers cleanly to the Canadian context.

The PMOA test sounds more objective than it is in practice. Many products have overlapping mechanisms, and subject matter experts within the same development team regularly disagree. What matters is that you document your classification rationale thoroughly before you approach Health Canada — reviewers expect to see a substantive scientific argument, not a conclusion with a footnote.

Two Regulatory Pathways, Very Different GMP Obligations

The stakes of the classification decision are real. Drug and device regulatory pathways in Canada carry materially different GMP frameworks, timelines, and data requirements.

Under the drug pathway, a new combination product typically requires a New Drug Submission (NDS). GMP compliance is governed by Health Canada’s Good Manufacturing Practices guidelines under Division 2 of Part C of the Food and Drug Regulations, supplemented by ICH Q7 for active pharmaceutical ingredient manufacturing and ICH Q10 for the pharmaceutical quality system. Manufacturers must hold a valid Drug Establishment Licence (DEL). Standard review timelines run approximately 300 review days under the standard Targeted Review Timeline, or considerably shorter under Priority Review for qualifying products.

Under the medical device pathway, Class III and Class IV products — the categories most combination products fall into — require a Premarket Review submission to the MDB. Class IV devices, representing the highest-risk tier, require a Quality Management System compliant with ISO 13485:2016, clinical evidence meeting the evidentiary thresholds set out in Schedule 1 of the Medical Devices Regulations, and a complete device history file. Review timelines for Class IV devices routinely run 300 to 500 days, and they’re not always predictable.

The GMP gap between the two frameworks deserves specific attention. Drug GMP requires a DEL, validated manufacturing processes aligned with GUI-0104 (Health Canada’s current GMP guidelines), and a fully functioning pharmaceutical quality system with defined specifications for every release test. Medical device manufacturing under ISO 13485 shares structural similarities — document control, change management, nonconformance handling — but differs considerably in risk management requirements (ISO 14971 is mandatory for medical devices), design control documentation, and post-market surveillance architecture.

If your combination product is classified as a device but manufactured with a substantial pharmaceutical component, you may need to satisfy elements of both frameworks simultaneously. That’s not a regulatory grey area — it’s an explicit expectation in some cases. Sponsors who discover this during submission preparation rather than during development planning lose months, sometimes more.

What This Means for CMO and CRO Quality Agreements

For contract manufacturing organizations and contract research organizations operating in Canada, combination products introduce contractual and quality agreement considerations that simply don’t arise with single-modality products.

Quality agreements between sponsors and CMOs must explicitly address which party owns responsibility for each regulatory pathway. If a device component is manufactured under ISO 13485 at one facility and a drug component under drug GMP at a second, the sponsor carries the burden of demonstrating that the combined article meets whichever regulatory requirements govern the final product. That requires upfront structural clarity — ideally established before the development phase is underway, not during submission preparation.

Three specific provisions CMOs and CROs should address in quality agreements for combination products:

Classification documentation ownership. Who prepares and maintains the PMOA rationale? In most cases this should be the sponsor, but the CMO’s regulatory function needs access to it for their own GMP and quality system files. Leaving this undefined is a routine inspection finding.

GMP bridge requirements. If the combination product is regulated as a drug but the device sub-component is manufactured at a facility licensed only under ISO 13485, Health Canada will want evidence that the device component meets applicable drug GMP requirements — or a documented scientific justification for why it doesn’t need to. That evidence needs to come from a specific party, by a specific date, and the quality agreement should say so.

Post-market obligations. Drug products distributed in Canada trigger Adverse Drug Reaction (ADR) reporting obligations under Section C.01.017 of the Food and Drug Regulations. Medical devices trigger Mandatory Problem Reporting under Section 59 of the Medical Devices Regulations. Combination products governed by dual frameworks may trigger both sets of obligations depending on how the adverse event is characterized. Your quality agreement needs to assign monitoring, signal detection, and filing responsibilities explicitly — and those assignments need to be reviewed any time the product’s regulatory classification is updated.

Canadian GMP inspectors increasingly ask about combination product classification rationale during routine DEL inspections, particularly for manufacturers who supply both drug and device markets. A clear, documented answer that everyone in the quality team can give consistently is not optional.

Practical Steps Before You Request Classification Guidance From Health Canada

Health Canada offers a pre-submission meeting process through the Office of Submissions and Intellectual Property (OSIP) for drug-pathway products, and a pre-submission program through the MDB for device-pathway products. Both are genuinely useful — but they work best when you arrive prepared.

Step 1 — Draft your PMOA rationale first. Document the product’s intended purpose, the mechanism of action for each component, and a comparative analysis of the pharmacological versus mechanical contributions to the primary clinical effect. Reference peer-reviewed literature where available. Your rationale doesn’t need to be final, but it needs to be substantive. Reviewers are not going to make your classification argument for you.

Step 2 — Review analogous international decisions. Health Canada pays close attention to FDA and EU MDR classification decisions for comparable products. Where international precedents support your proposed classification, cite them explicitly. Where they conflict with your proposed classification, explain the scientific or clinical basis for why the Canadian context differs — not just that it does.

Step 3 — Identify development-phase GMP requirements early. Combination product components manufactured for clinical trial use must comply with applicable GMP standards: drug GMP for investigational drug components, ISO 13485 for investigational device components. Getting clarity on this before your clinical manufacturing contracts are signed prevents expensive facility qualification work mid-trial.

Step 4 — Assign a single regulatory lead internally. Someone needs to own the drug file, and potentially someone else needs to own the device file. These teams often speak different regulatory languages and operate on different submission timelines. A single accountable regulatory lead for the combined product — with clear escalation paths to both drug and device subject matter experts — is standard practice among experienced CROs and CMOs working in this space. Without it, critical decisions fall between teams and get made inconsistently.

Combination products aren’t inherently more difficult to bring to market in Canada than anywhere else. But they don’t reward ambiguity. A classification decision that’s well-reasoned, clearly documented, and confirmed through Health Canada’s pre-submission process is worth the investment — it’s the foundation everything else is built on.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Pharmaceutical Analytical Testing for Canadian Drug Submissions — ISO 17025-accredited contract laboratory supporting NDS, ANDS, and CTA filings across Canada and the US
• EU Medical Device Regulation and MDR Compliance — Specialist guidance on EU MDR classification, technical documentation, and notified body submissions for European market entry